Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study
Journal
European journal of cancer (Oxford, England : 1990)
Journal Volume
172
Pages
276
Date Issued
2022-09
Author(s)
Tan, Daniel S W
Kim, Sang-We
Ponce Aix, Santiago
Sequist, Lecia V
Smit, Egbert F
Hida, Toyoaki
Toyozawa, Ryo
Felip, Enriqueta
Wolf, Juergen
Grohé, Christian
Leighl, Natasha B
Riely, Gregory
Cui, Xiaoming
Zou, Mike
Ghebremariam, Samson
O'Sullivan-Djentuh, Leslie
Belli, Riccardo
Giovannini, Monica
Kim, Dong-Wan
Abstract
Nazartinib, a novel third-generation EGFR-tyrosine kinase inhibitor, previously demonstrated antitumor activity and manageable safety in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who received ≤ 3 prior lines of systemic therapy. Herein, we report phase 2 efficacy and safety of first-line nazartinib.
Subjects
EGFR; NSCLC; Nazartinib; Third-generation EGFR-TKI; Treatment-naive
SDGs
Publisher
ELSEVIER SCI LTD
Type
journal article